Caliway Biopharmaceuticals Co., Ltd. (TPEX: 6919)
541.00
-14.00 (-2.52%)
Sep 10, 2024, 2:59 PM CST
Caliway Biopharmaceuticals Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 2,650 | 3,422 | 655.05 | 594.91 | 93.56 | 21.69 |
Short-Term Investments | 689.4 | 289.4 | 456.18 | - | - | - |
Cash & Short-Term Investments | 3,340 | 3,712 | 1,111 | 594.91 | 93.56 | 21.69 |
Cash Growth | 283.70% | 234.01% | 86.79% | 535.87% | 331.36% | - |
Accounts Receivable | 4.52 | 7.89 | 3.12 | - | - | 3.2 |
Other Receivables | - | - | - | - | - | 4.46 |
Receivables | 4.52 | 7.89 | 3.12 | - | - | 7.66 |
Inventory | 5.66 | 1.02 | 2.81 | 0.05 | 2.53 | 0.02 |
Other Current Assets | 17.45 | 23.16 | 14.87 | 10.32 | 14.96 | 9.08 |
Total Current Assets | 3,367 | 3,744 | 1,132 | 605.27 | 111.05 | 38.45 |
Property, Plant & Equipment | 73.49 | 80.41 | 99.6 | 106.38 | 114.68 | 128.99 |
Other Intangible Assets | - | - | - | - | 0.07 | 1.66 |
Other Long-Term Assets | 2.89 | 2.46 | 1.46 | 1.26 | 1.26 | 1.26 |
Total Assets | 3,444 | 3,827 | 1,233 | 712.9 | 227.05 | 170.35 |
Accounts Payable | 1.72 | 1.7 | 2.53 | 0.33 | 0.74 | 1.04 |
Accrued Expenses | - | - | - | 30.98 | 45.14 | 19.96 |
Short-Term Debt | - | - | - | - | - | 5 |
Current Portion of Long-Term Debt | - | - | - | 1.17 | 7.97 | 74.72 |
Current Portion of Leases | 8.79 | 8.58 | 8.22 | 7.03 | 6.79 | 6.49 |
Current Unearned Revenue | 9.41 | 1.03 | 4.5 | - | - | - |
Other Current Liabilities | 60.43 | 62.37 | 33.11 | 0.16 | 3.82 | 3.2 |
Total Current Liabilities | 80.35 | 73.68 | 48.36 | 39.67 | 64.45 | 110.4 |
Long-Term Debt | - | - | - | 3.55 | 83.95 | 30.41 |
Long-Term Leases | 7.46 | 11.87 | 20.46 | 25.02 | 32.06 | 38.85 |
Total Liabilities | 87.81 | 85.55 | 68.82 | 68.24 | 180.46 | 179.66 |
Common Stock | 697.19 | 696.62 | 615.55 | 535.93 | 312.17 | 244.71 |
Additional Paid-In Capital | 3,053 | 3,271 | 834.46 | 217.47 | 106.85 | 18.6 |
Retained Earnings | -395.12 | -227.31 | -286.16 | -107.41 | -371.05 | -272.56 |
Treasury Stock | -0.06 | -0.07 | -0.08 | -0.09 | - | - |
Comprensive Income & Other | 1.09 | 0.81 | 0.49 | -1.24 | -1.38 | -0.06 |
Shareholders' Equity | 3,356 | 3,741 | 1,164 | 644.66 | 46.6 | -9.31 |
Total Liabilities & Equity | 3,444 | 3,827 | 1,233 | 712.9 | 227.05 | 170.35 |
Total Debt | 16.25 | 20.46 | 28.68 | 36.78 | 130.76 | 155.46 |
Net Cash (Debt) | 3,324 | 3,691 | 1,083 | 558.13 | -37.2 | -133.77 |
Net Cash Growth | 292.93% | 240.96% | 93.96% | - | - | - |
Net Cash Per Share | 25.17 | 29.79 | 9.24 | 6.07 | -0.50 | -1.91 |
Filing Date Shares Outstanding | 139.42 | 139.3 | 123.11 | 107.16 | 83.29 | 69.92 |
Total Common Shares Outstanding | 139.42 | 139.3 | 123.11 | 107.16 | 83.29 | 69.92 |
Working Capital | 3,287 | 3,670 | 1,084 | 565.6 | 46.6 | -71.96 |
Book Value Per Share | 24.07 | 26.86 | 9.46 | 6.02 | 0.56 | -0.13 |
Tangible Book Value | 3,356 | 3,741 | 1,164 | 644.66 | 46.53 | -10.96 |
Tangible Book Value Per Share | 24.07 | 26.86 | 9.46 | 6.02 | 0.56 | -0.16 |
Machinery | 136.25 | 129.99 | 121.55 | 112.76 | 76.42 | 74.25 |
Construction In Progress | 2.27 | 1.14 | 1.82 | 0.3 | 31.29 | 31.67 |
Source: S&P Capital IQ. Standard template. Financial Sources.